Regarding the molecular mechanisms and clinical features of tumor suppressor gene inactivation, all of the following statements are correct EXCEPT:

Explanation

## Tumor Suppressor Gene Mechanisms: Distinguishing Fact from Fiction ### Overview **Key Point:** Tumor suppressors regulate cell cycle checkpoints, DNA repair, apoptosis, and differentiation. Understanding their specific subcellular localization and function is critical for NEET PG. ### Detailed Analysis | Gene | Function | Correct Statement | Status | | --- | --- | --- | --- | | NF1 | RAS-GAP | Loss → RAS hyperactivation → neurofibromas | ✓ Correct | | WT1 | Transcription factor | Mutations → Wilms tumor + WAGR features | ✓ Correct | | CDKN2A/p16 | CDK inhibitor | Inactivation → CDK4/6 hyperactivity → G1/S escape | ✓ Correct | | BRCA1/BRCA2 | **Nuclear** HR repair | **Mitochondrial DNA repair** claim | ✗ Wrong | ### The Critical Error: BRCA Subcellular Localization **High-Yield:** BRCA1 and BRCA2 function **exclusively in nuclear DNA repair**, specifically homologous recombination (HR) repair of double-strand breaks (DSBs) in the nucleus. **Why This Matters:** - BRCA1/BRCA2 are nuclear proteins; they do not localize to mitochondria - Their loss causes **nuclear genomic instability** (chromosome rearrangements, deletions, amplifications), not mitochondrial dysfunction - The mechanism of cancer predisposition is HR deficiency → unrepaired DSBs → chromosomal chaos → malignant transformation **Warning:** The statement conflates: - ~~Mitochondrial DNA repair~~ (not BRCA function) - **Nuclear DNA repair** (correct BRCA function) This is a classic distractor designed to test whether students understand subcellular localization of repair machinery. ### Why the Other Options Are Correct 1. **NF1:** Encodes neurofibromin, a RAS-GAP protein. Loss → RAS remains in active GTP-bound state → uncontrolled growth → neurofibromas and increased malignancy risk. 2. **WT1:** Wilms tumor suppressor; mutations cause: - Wilms tumor (embryonal kidney cancer) - WAGR syndrome (contiguous gene deletion including WT1 and PAX6) - Denys-Drash syndrome (WT1 point mutations + genitourinary dysgenesis) 3. **CDKN2A/p16:** CDK inhibitor that binds CDK4/6, preventing their interaction with cyclin D. Loss removes this checkpoint → CDK4/6 hyperactivity → RB hyperphosphorylation → uncontrolled S-phase entry, even if RB is intact.